Using the Alzheimer’s Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer’s disease
Open accessAbstract
INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020. METHODS: We identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion. RESULTS: Disease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity. DISCUSSION: ADNI has had a profound impact in improving clinical trials for AD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The benefit of acetylcholinesterase inhibitor medications is fairly limited; donepezil, rivastigmine, and galantamine have the potential to marginally improve cognition, ability to perform routine activities, and behavior in cases with mild-to-moderate Alzheimer's disease for intervals of 6 to 18 months.
“The benefit of these medications is fairly limited, and the studies have reported that donepezil, rivastigmine, and galantamine have the potential to marginally improve cognition, ability to perform routine activities, and behavior in cases with mild-tomoderate AD for intervals of 6 to 18 months [12].”
From Unlocking the Therapeutic Potential of Medicinal Plants for Alzheimer’s Disease: Preclinical to Clinical Trial Insights (2023) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 208 · Cited by 184
Research works printed but not linked: 4
- [31]Hadjichrysanthou C, Evans S, Bajaj S, et al. The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. Alzheimer's Res Ther. 2020; 12: 1‐ 16. PMC7293779 32534594
- [202]Illán‐Gala I, Pegueroles J, Montal V, et al. Challenges associated with biomarker‐based classification systems for Alzheimer's disease. Alzheimer's Dement. 2018; 21: 346‐ 357. PMC6114028 30175226
- [203]Hayes JP, Moody JN, Roca JG, Hayes SM, Alzheimer's Disease Neuroimaging I. Body mass index is associated with smaller medial temporal lobe volume in those at risk for Alzheimer's disease. NeuroImage Clin. 2019; 25: 102156. 31927127 PMC6953956
- [204]Lao PJ, Brickman AM, Initiative AsDN. Multimodal neuroimaging study of cerebrovascular disease, amyloid deposition, and neurodegeneration in Alzheimer's disease progression. Alzheimer's Dement. 2018; 10: 638‐ 646. PMC6215981 30417071
- Authors
- Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., Morris, J. C., Okonkwo, O., Perrin, R. J., Petersen, R. C., Rivera‐Mindt, M., Saykin, A. J., Shaw, L. M., Toga, A. W., Tosun, D., Trojanowski, J. Q., & Initiative, A. D. N.
- Affiliations
- San Francisco VA Medical Center (US)
- University of Southern California (US)
- University of California, Davis (US)
- Broad Institute (US)
- Mayo Clinic (US)
- University of California, Berkeley (US)
- Washington University in St. Louis (US)
- University of Wisconsin–Madison (US)
- Department of Psychology Fordham University New York New York USA
- Indiana University Indianapolis (US)
- University of Pennsylvania (US)
- University of California, San Francisco (US)
- Corresponding author
- Weiner, Michael W.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2021-09-28
- Volume
- 18
- Issue
- 4
- Pages
- 824-857
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC9158456
- OpenAlex
- W3201798407
- Cited by
- 184
- References
- 208
- Citations by year
- 2026: 34 · 2025: 46 · 2024: 45 · 2023: 45 · 2022: 13 · 2021: 1
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
- Funders
- National Institutes of Health (U19‐AG024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Neuroimaging, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
